Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Di Perri

Showing results (231-240 of 358) with videos related to

Pageof 36
Sort By:
Le Infezioni in Medicina|March 30, 2017
Pharmacogenomic influence on sepsis outcome in critically ill patientsSarah Allegra, Giovanna Fatiguso, Lorena Baietto, et al.
Antimicrobial Agents and Chemotherapy|May 18, 2022
The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation StudyAmedeo De Nicolò, Andrea Calcagno, Ilaria Motta, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 12, 2009
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasmaSilvia De Francia, Antonio D'Avolio, Francesca De Martino, et al.
The Journal of Obstetrics and Gynaecology Research|November 23, 2021
Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative studyStefano Cosma, Andrea Roberto Carosso, Jessica Cusato, et al.
Journal of the International AIDS Society|November 15, 2014
Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 yearsBrian Gazzard, Pierre Marie Girard, Giovanni Di Perri, et al.
AIDS (London, England)|December 5, 2015
Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairmentAndrea Calcagno, Jessica Cusato, Letizia Marinaro, et al.
Journal of Reproductive Immunology|February 14, 2021
Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to deliveryStefano Cosma, Andrea Roberto Carosso, Silvia Corcione, et al.
HIV Clinical Trials|August 26, 2010
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT studyJuan Sierra-Madero, Giovanni Di Perri, Robin Wood, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2008
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patientsDaniel Gonzalez de Requena, Stefano Bonora, Antonella Castagna, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patientsEmanuele Focà, Andrea Calcagno, Andrea Bonito, et al.
Pageof 36

Showing results (231-240 of 358) with videos related to

Sort By:
Pageof 36
Le Infezioni in Medicina|March 30, 2017
Pharmacogenomic influence on sepsis outcome in critically ill patientsSarah Allegra, Giovanna Fatiguso, Lorena Baietto, et al.
Antimicrobial Agents and Chemotherapy|May 18, 2022
The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation StudyAmedeo De Nicolò, Andrea Calcagno, Ilaria Motta, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|May 12, 2009
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasmaSilvia De Francia, Antonio D'Avolio, Francesca De Martino, et al.
The Journal of Obstetrics and Gynaecology Research|November 23, 2021
Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative studyStefano Cosma, Andrea Roberto Carosso, Jessica Cusato, et al.
Journal of the International AIDS Society|November 15, 2014
Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 yearsBrian Gazzard, Pierre Marie Girard, Giovanni Di Perri, et al.
AIDS (London, England)|December 5, 2015
Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairmentAndrea Calcagno, Jessica Cusato, Letizia Marinaro, et al.
Journal of Reproductive Immunology|February 14, 2021
Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to deliveryStefano Cosma, Andrea Roberto Carosso, Silvia Corcione, et al.
HIV Clinical Trials|August 26, 2010
Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT studyJuan Sierra-Madero, Giovanni Di Perri, Robin Wood, et al.
The Journal of Antimicrobial Chemotherapy|May 20, 2008
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patientsDaniel Gonzalez de Requena, Stefano Bonora, Antonella Castagna, et al.
The Journal of Antimicrobial Chemotherapy|September 30, 2017
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patientsEmanuele Focà, Andrea Calcagno, Andrea Bonito, et al.
Pageof 36